Tau Aggregation Inhibition in Neurodegenerative Disorders

Tau is a microtubule-associated protein that stabilises neuronal cytoskeletal architecture. In a range of neurodegenerative disorders collectively known as tauopathies, tau undergoes aberrant post-translational modifications and self-assembly into insoluble filaments that form neurofibrillary tangles. These aggregates disrupt axonal transport, impair synaptic function and trigger neuronal loss. Inhibition of tau aggregation has therefore emerged as a promising strategy for disease modification, aiming to prevent or reverse filament formation and restore neuronal homeostasis. Approaches under investigation encompass small-molecule ligands designed to interfere with key tau–tau interactions, peptide or peptidomimetic inhibitors that bind aggregation-prone segments, immunotherapeutics targeting extracellular tau seeds and molecular chaperones that enhance clearance. Recent advances have elucidated structural determinants of tau assembly, enabling rational inhibitor design and high-throughput screening of novel scaffolds. Preclinical studies in cellular and animal models demonstrate that effective tau aggregation inhibitors can attenuate tangle burden, preserve synaptic integrity and improve cognitive endpoints. Translation to clinical application remains challenging, yet ongoing trials and refined molecular designs hold potential for first-in-class tau-directed therapies in Alzheimer’s disease and related disorders.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Tau Aggregation Inhibition in Neurodegenerative Disorders publication trend

The graph below shows the total number of articles in tau aggregation inhibition in neurodegenerative disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Tau protein: A neuronal microtubule-associated protein that stabilises axonal structure and is prone to pathological aggregation when hyperphosphorylated.

Neurofibrillary tangles: Intracellular inclusions composed of aggregated, abnormally modified tau filaments observed in Alzheimer’s disease and other tauopathies.

Intrinsically disordered protein: A protein lacking a fixed tertiary structure under physiological conditions, often adopting multiple conformations that can facilitate aggregation.

Thioflavin T fluorescence assay: A biochemical assay in which the dye Thioflavin T exhibits enhanced fluorescence upon binding to amyloid β-sheet structures, used to monitor aggregation kinetics.

Hydromethylthionine mesylate (HMTM): A small-molecule tau aggregation inhibitor that binds to tau filaments and has demonstrated in vivo efficacy in reducing tangle burden and preserving neuronal function.

References

1. Molecular Deformation Is a Key Factor in Screening Aggregation Inhibitor for Intrinsically Disordered Protein Tau. ACS Central Science (2024).
2. Tau-aggregation inhibitors derived from Streptomyces tendae MCCC 1A01534 protect HT22 cells against okadaic acid-induced damage. International Journal of Biological Macromolecules (2023).
3. Neuroprotection of Cholinergic Neurons with a Tau Aggregation Inhibitor and Rivastigmine in an Alzheimer’s-like Tauopathy Mouse Model. Cells (2024).